Can Weight Watchers shape up in the GLP-1 era?

April 2, 2026·1 hr 3 min·4 clips

Weight Watchers data shows members who combine the GLP-1 success program with medication lose 29% more weight than those who use medication alone.

Weight Watchers enters the episode under pressure. The host starts with a company that used to be the legacy name in weight loss treatment, then lost ground as GLP-1 medications changed the market around it. The brand history gets concrete quickly. Oprah Winfrey's board connection, the WW rebrand, Eli Lilly, Novo Nordisk, Rho, Hims and Hers, and Noom all come into the setup. Bankruptcy is not tossed in as background noise. The May 2025 Chapter 11 filing, framed around eliminating around $1.5 billion in debt, becomes the reason the repositioning question matters. The guest shifts the conversation to member behavior. GLP-1 use is not treated like one clean arc. He describes people staying off medication, stopping, regaining, and restarting. Maintenance is the hard part. His case is that support still has a role when medication is active, paused, stretched out, or picked up again later. That is the opening Weight Watchers is trying to claim. The company comes across less like the old points and coaching brand and more like a service trying to fit itself around GLP-1 use. The virtual clinic is part of that pitch. The guest ties GLP-1 success programming and Med Plus virtual clinic support to each member's health profile and preferences. The host keeps it analytical, linking the answer to a broader reset in how people talk about GLP-1 lifespan and long term support. The closing question shifts the tone. Asked what people misunderstand about Weight Watchers, the guest has to name the one thing he wants corrected. The final beat zooms out to cardiometabolic health, weight loss, Alzheimer's disease, oncology, and healthcare innovation.

As heard by us

Weight Watchers' GLP-1 reset feels less like a comeback than a test of relevance.

The episode treats Weight Watchers as a company trying to find its footing after GLP-1s rewrote the market around it. It does not lean on nostalgia; it keeps the focus on strategy, pressure, and what the business has to answer next.

Read the full review in PlayNext →

Why you'd press play

Weight Watchers' GLP-1 reset is still being written in 2026.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The MM+M Podcast